Choi Eun Jeong, Han Jung Yeol
Korean MotherSafe Counselling Center, Pregnancy & Breastfeeding Medicines Information Center, Seoul, Korea.
Department of Obstetrics and Gynaecology, Hanmaeum Changwon Hospital, Changwon, Korea.
Obstet Gynecol Sci. 2021 Mar;64(2):201-208. doi: 10.5468/ogs.20247. Epub 2021 Jan 8.
Isotretinoin is commonly prescribed worldwide despite its notorious teratogenicity. A risk management program (RMP) was introduced in Korea to prevent isotretinoin use during pregnancy. Here, we evaluate the compliance of Korean women with the recommendations of the RMP.
This prospective cohort study was conducted between April 2019 and June 2020. Thirty-six and 82 patients received the prescription before and after the introduction of RMP, respectively.
There was a significant difference in the total number of days for which isotretinoin was prescribed before and after the RMP was introduced (68.8±100.9 and 28.0±26.1 days, respectively). However, 1.43% (120/8,394) of the total patients contacted by the teratology information services were exposed to isotretinoin on an average.
The proportion of patients exposed to isotretinoin did not change, and there was no significant change in compliance, with the implementation of the RMP during the study period. Further studies are needed to evaluate the effectiveness of the RMP in the long term.
异维A酸尽管具有众所周知的致畸性,但在全球范围内仍被广泛处方。韩国引入了一项风险管理计划(RMP)以防止孕期使用异维A酸。在此,我们评估韩国女性对RMP建议的依从性。
这项前瞻性队列研究于2019年4月至2020年6月进行。分别有36例和82例患者在RMP引入之前和之后接受了处方。
引入RMP前后,异维A酸处方的总天数存在显著差异(分别为68.8±100.9天和28.0±26.1天)。然而,致畸信息服务机构联系的所有患者中,平均有1.43%(120/8394)接触过异维A酸。
在研究期间,接触异维A酸的患者比例没有变化,RMP实施后的依从性也没有显著变化。需要进一步研究以评估RMP的长期有效性。